Unicycive Therapeutics Inc

詳細情報 Unicycive Therapeutics Inc 企業名

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

企業情報

企業コードUNCY

会社名Unicycive Therapeutics Inc

上場日Jun 17, 2021

設立日2016

最高経営責任者「CEO」Dr. Shalabh Gupta, M.D.

従業員数22

証券種類Ordinary Share

決算期末Jun 17

本社所在地4300 El Camino Real, Suite 210

都市LOS ALTOS

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号94022

電話番号16503840642

ウェブサイトhttps://unicycive.com/

企業コードUNCY

上場日Jun 17, 2021

設立日2016

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Sandeep (Steve) Laumas, M.D.

Independent Director

10.58K

--

Dr. Pramod Gupta, Ph.D.

Executive Vice President - Pharmaceutical and Business Operations

4.18K

--

Dr. Shalabh Gupta, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

--

Mr. John Townsend

Chief Financial Officer

--

Mr. Doug Jermasek

Executive Vice President - Corporate Strategy

--

Dr. Gaurav Aggarwal, M.D.

Independent Director

--

Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Sandeep (Steve) Laumas, M.D.

Independent Director

10.58K

--

Dr. Pramod Gupta, Ph.D.

Executive Vice President - Pharmaceutical and Business Operations

4.18K

--

Dr. Shalabh Gupta, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

--

Mr. John Townsend

Chief Financial Officer

--

Mr. Doug Jermasek

Executive Vice President - Corporate Strategy

--

Dr. Gaurav Aggarwal, M.D.

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Thu, May 15

株主統計

種類

株主統計

比率

Vivo Capital, LLC

8.90%

Great Point Partners, LLC

8.60%

Octagon Capital Advisors LP

7.83%

Nantahala Capital Management, LLC

7.36%

Gupta (Shalabh K)

4.68%

Other

62.63%

株主統計

比率

Vivo Capital, LLC

8.90%

Great Point Partners, LLC

8.60%

Octagon Capital Advisors LP

7.83%

Nantahala Capital Management, LLC

7.36%

Gupta (Shalabh K)

4.68%

Other

62.63%

種類

株主統計

比率

Hedge Fund

34.78%

Venture Capital

12.98%

Individual Investor

4.93%

Investment Advisor/Hedge Fund

1.61%

Investment Advisor

0.12%

Research Firm

0.11%

Other

45.47%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

61

6.96M

54.53%

-647.33K

2025Q1

65

6.78M

64.49%

-1.12M

2024Q4

62

69.04M

66.51%

+542.97K

2024Q3

57

54.12M

55.45%

+17.71M

2024Q2

48

26.33M

50.66%

-3.75M

2024Q1

46

28.58M

99.15%

+4.37M

2023Q4

45

24.82M

96.62%

+1.55M

2023Q3

47

22.73M

96.91%

+9.25M

2023Q2

42

9.36M

61.47%

-512.55K

2023Q1

38

9.94M

65.95%

+1.31M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Vivo Capital, LLC

1.14M

8.9%

+140.00K

+14.04%

Mar 31, 2025

Great Point Partners, LLC

1.10M

8.6%

--

Mar 31, 2025

Octagon Capital Advisors LP

1.00M

7.83%

--

Mar 31, 2025

Nantahala Capital Management, LLC

939.20K

7.36%

-100.00K

-9.62%

Mar 31, 2025

Gupta (Shalabh K)

597.25K

4.68%

-100.00

-0.02%

Apr 30, 2025

Logos Global Management LP

507.89K

3.98%

--

Mar 31, 2025

Walleye Capital LLC

409.43K

3.21%

-90.57K

-18.11%

Mar 31, 2025

Rosalind Advisors, Inc.

242.49K

1.9%

+242.49K

--

Apr 30, 2025

SilverArc Capital Management, LLC

241.35K

1.89%

-7.32K

-2.94%

Mar 31, 2025

Acuta Capital Partners, LLC

235.29K

1.84%

+4.99K

+2.17%

Mar 31, 2025

詳細を見る

4.430USD

Unicycive Therapeutics Inc

4.430

概要

企業名

金融